CONDUIT PHARMACEUTICALS INC. (CDT) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 25 transactions totaling $4.6M, demonstrating a bearish sentiment with -$4.6M in net insider flow. The most recent transaction on Dec 8, 2025 involved a transaction of 224,800 shares valued at $402.4K.
No significant insider buying has been recorded for CDT in the recent period.
No significant insider selling has been recorded for CDT in the recent period.
Based on recent SEC filings, insider sentiment for CDT is bearish with an Insider Alignment Score of 0/100 and a net flow of -$4.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at CONDUIT PHARMACEUTICALS INC. (CDT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading CDT stock, having executed 25 transactions in the past 90 days. The most active insider is Capital Ltd. Corvus (Executive), who has made 13 transactions totaling $5.0M.
Get notified when executives and directors at CDT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Ltd. Corvus Capital | Executive | Award | 224,800 | $1.79 | $402.4K | |
| Sep 19, 2025 | Bligh James | Executive | Award | 480,000 | $N/A | $0 | |
| Sep 19, 2025 | Regan Andrew | Executive | Award | 1,120,000 | $0.69 | $772.8K | Large |
| Aug 12, 2025 | Chiavacci Farley Chele | Executive | Award | 35,000 | $N/A | $0 | |
| Aug 12, 2025 | C. Lewis-hall Freda | Executive | Award | 35,000 | $N/A | $0 | |
| Aug 12, 2025 | Jeremy Fry Simon | Executive | Award | 35,000 | $N/A | $0 | |
| Jul 17, 2024 | Ltd. Corvus Capital | Executive | Sale | 1,514,100 | $0.26 | $393.7K | |
| Jul 16, 2024 | Ltd. Corvus Capital | Executive | Sale | 10,244,392 | $0.32 | $3.3M | Large |
| Jul 15, 2024 | Ltd. Corvus Capital | Executive | Sale | 1,005,200 | $0.25 | $251.3K | |
| Jul 12, 2024 | Ltd. Corvus Capital | Executive | Sale | 1,389,820 | $0.25 | $347.5K | |
| Jul 11, 2024 | Ltd. Corvus Capital | Executive | Sale | 300,000 | $0.29 | $87.0K | |
| Jul 11, 2024 | Ltd. Corvus Capital | Executive | Sale | 582,952 | $0.30 | $174.9K | |
| Jul 10, 2024 | Ltd. Corvus Capital | Executive | Sale | 150,000 | $0.33 | $49.5K | |
| Jul 9, 2024 | Ltd. Corvus Capital | Executive | Sale | 77,681 | $0.44 | $34.2K | |
| Jul 8, 2024 | Ltd. Corvus Capital | Executive | Sale | 35,923 | $0.51 | $18.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 10 | $4.6M | 79.8% |
Award(A) | 10 | $1.2M | 20.2% |
Other(J) | 3 | $0 | 0.0% |
Disposition(D) | 1 | $0 | 0.0% |
Exercise(M) | 1 | $0 | 0.0% |
Insider selling pressure at CONDUIT PHARMACEUTICALS INC. has increased, with 8 insiders executing 25 transactions across all time. Total sales of $4.6M significantly outpace purchases of $0, resulting in a net outflow of $4.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.